NewsAIM-Listed Erectile Dysfunction Firm Poised To Enter Global CBD...

AIM-Listed Erectile Dysfunction Firm Poised To Enter Global CBD Market


A SKIN gel designed to boost male potency has been approved by UK and European regulators leading to a sharp rise in the shares of its maker.

AIM-listed Futura Medical has seen its stock price increase by over 200% after securing approval for over-the-counter sales of MED3000 – with hopes it will secure US approval within weeks.

And, following successful trials using MED3000’s proprietary gel-based DermaSys with CBD, Futura plans to target the skin care, cosmetics, pain and inflammation markets with its CBD100 range.

Futura’s Shares Have Risen Sharply

CBD Market Growing Rapidly

James Barder, CEO of Surrey-based Futura Medical, told BusinessCann: “Our studies demonstrated highly-efficient penetration of cannabidiol into and through the skin, superior to an established, marketed, comparator product. 

“Futura is in discussions with our joint venture partner over both the next steps from a development and also commercial standpoint, and we hope to update the market soon. 

“The market for cannabidiol products is growing rapidly, and is primarily driven by the increase in the usage of cannabidiol in medical applications, supplements, beverages and skin care.”

MED3000 is being seen as the biggest recent breakthrough in the treatment of erectile dysfunction working within 10 minutes – six times faster than the market leader Viagra.

‘Better Than Blue Pill’

This follows a successful clinical trial during which 1,000 participants, in 60 centres across nine countries, experienced ‘even better outcomes than anticipated’. Futura says it is on course for full certification by the end of May.

Futura’s shares rose from 18p to over 60p following the announcement of EU and UK approval last week; March 18.

Mr Barder added: “An intellectual property filing has now been made covering various unique aspects of the CBD100 gel formulation.

“The EU is set to provide a regulatory update for cannabidiol use in cosmetics during this year, and Futura believe that a gel that has been formulated using strict pharmaceutical development principles with strong delivery characteristics, stability and high quality could be a very attractive commercial proposition when compared to current market incumbents in either cosmetic or more traditional pharmaceutical markets for cannabidiol such as pain and inflammation.”

Transdermal delivery is Futura’s speciality. DermaSys is a gel-based technology based on ‘volatile solvent and, or, penetration enhancer components’ tailored to suit the specific therapeutic indication, speed of onset and duration of action for each product. 

The company’s portfolio includes pain relievers TPR100 and TIB200, formulated with diclofenac and ibuprofen, respectively, and shown to provide fast, effective and long-lasting relief when delivered using DermaSys, says Futura.

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.


Please enter your comment!
Please enter your name here

Latest news

Why Can CBD Be A ‘Cure-For-All’ In Europe – But Not The United States?

By Liebe Griebenauw and Peter McCusker FOUR firms have been sanctioned in the latest crackdown by the United States Food...

Markets: PepsiCo Launches German Hemp Drink, Curaleaf’s $130m Backer, Organigram, Canopy Growth, Fyllo et al…

FOLLOWING its recent purchase of UK cannabis firm EMMAC Life Sciences, Curaleaf has now secured an additional $130m from...

Euro Cannabis Leader Alfredo Pascual To Join UK Investor With £12m-Plus To Deploy

UK investment fund Fast Forward Innovations has added Alfredo Pascual - one of Europe’s leading cannabis industry figures -...

Love Hemp Raises £5m With A London Stock Exchange Flotation In Sight

FAST-GROWING UK CBD business Love Hemp has unveiled plans to list on the London Stock Exchange backed by an...

CBD Marketplace Mellow Expanding Rapidly With New B2B and B2C Offerings

THE marketplace entrepreneurs behind the mellow platform are diversifying with the launch of a new e-commerce service for partner...

Dutch/Canadian Duopoly In European Medicinal Cannabis Market In Retreat

THE European medicinal cannabis supply stranglehold once enjoyed by Canada and the Netherlands is being disrupted, concludes Prohibition Partners...

Must read

Why Can CBD Be A ‘Cure-For-All’ In Europe – But Not The United States?

By Liebe Griebenauw and Peter McCusker FOUR firms have been...

Euro Cannabis Leader Alfredo Pascual To Join UK Investor With £12m-Plus To Deploy

UK investment fund Fast Forward Innovations has added Alfredo...

You might also likeRELATED
Recommended to you